CardioDx has announced it has secured $35 million in total equity financing.

CardioDx, headquartered in Redwood City, Calif., is a molecular diagnostics company specializing in cardiovascular genomics.

Participants in this round of financing included Alberta Investment Management Corp. and the company’s existing investors.

CardioDx indicated the funds will be used to broaden the commercial use of Corus CAD, a blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as augment the company’s research efforts.